vimarsana.com
Home
Live Updates
FDA Approves Drug-Device Combo to Detect Residual Cancer Aft
FDA Approves Drug-Device Combo to Detect Residual Cancer Aft
FDA Approves Drug-Device Combo to Detect Residual Cancer After Lumpectomy
The FDA has approved Lumisight (pegulicianine), an optical imaging agent, to illuminate residual breast cancer.
Related Keywords
Howard Hechler ,
Drug Administration ,
Lumicell Direct Visualization System ,
Chief Operating Officer ,